<DOC>
	<DOCNO>NCT01045915</DOCNO>
	<brief_summary>The objective present trial evaluate local general safety intratumoural electrotransfer increase dos Plasmid AMEP patient suffer advanced metastatic melanoma identify dos could effective cutaneous lesion man .</brief_summary>
	<brief_title>Safety Efficacy Study Electrotransfer Plasmid AMEP Treat Advanced Metastatic Melanoma</brief_title>
	<detailed_description>In open , multicentre , dose escalation study , successive cohort 3 patient suffer advanced metastatic melanoma electrotransferred increase dos Plasmid AMEP cutaneous melanoma lesion 2 divide dos one week interval .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Male nonpregnant , nonbreast feeding female ; 2 . Aged 18 75 year ; 3 . Stage IIIB , stage IIIC stage IV melanoma : At least 2 cutaneous subcutaneous non necrotic accessible tumour ; Tumour size 1 1.5 cm diameter ; No minimum distance 2 select lesion ; 4 . Progressive melanoma respond previous treatment patient refuse therapy ; 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 ; 6 . For woman childbearing age : effective contraception method ( oral contraception intrauterine device ) use 2 month 1st administration maintain 3 month last administration Plasmid AMEP ; 7 . Having give write informed consent . 1 . Patients benefit melanoma treatment include surgery ; 2 . Significant cardiac arrhythmia , electronic pacemaker , defibrillator , implant electronic device ; 3 . Recent ( less 6 month ) acute vascular disease ( stroke , MI… ) ; 4 . Advanced peripheral arterial disease , venous ulcer , scleroderma ; 5 . History treatment seizure within last 5 year ; 6 . Clinically significant abnormality prestudy full physical examination ; 7 . Any clinically significant ECG abnormality ; 8 . Prior systemic therapy antineoplastic treatment within last 4 week , radiotherapy surgery unrelated field question allow ; 9 . Abnormal renal function ( creatinine plasma level &gt; ULN ) ; 10 . Abnormal liver function test ( follow ) : PT &lt; 70 % , ASAT , ALAT , alkaline phosphatase , GGT and/or total bilirubin &gt; ULN absence liver metastasis ; PT &lt; 70 % , ASAT , ALAT &gt; 2 ULN , alkaline phosphatase &gt; 1.5 ULN , GGT &gt; 5 ULN and/or total bilirubin &gt; 3 ULN case liver metastasis ; 11 . Abnormal bone marrow function : haemoglobin &lt; 10g/dL , WBC &lt; 3.109 /L and/or platelet count &lt; 100.103 /L ; 12 . Clinically significant abnormality prestudy laboratory test ; 13 . Evidence significant active infection ( e.g. , pneumonia , wound abscess , etc ) ; 14 . Intractable coagulopathy ; 15 . Any significant disease , include psychiatric dermatology disease may affect proper evaluation efficacy safety ; 16 . Patients participate another clinical trial last 30 day prior enrolment present clinical trial ; 17 . Patients unwilling unable comply protocol requirement schedule visit . Note : patient brain metastasis , wait therapy ( i.e . isolated limb perfusion ) may include .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Stage IIIB , stage IIIC stage IV melanoma</keyword>
	<keyword>Progressive melanoma respond previous treatment</keyword>
</DOC>